49 patents currently held
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2032. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2032
Next term end
24
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2038 · High confidence
Also notable
Ends May 2040 · High confidence
Also notable
Ends Jan 2035 · High confidence
Reducing the Accumulation of Imines/Enamines for the Production of Amino Acids or Amino Acid-Derived Products
US 11,781,163
A family of 32 related applications built on the 2023 grant. Protection runs to 2038.
Method and System for Extracting Long Chain Dicarboxylic Acid
US 11,229,881
Granted 2022. Computed term ends 2040.
Method for Purifying 1,5-Pentanediamine and 1,5-Pentanediamine
US 10,538,481
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 3 to 12, 2027 · next Mar 3
- 1 fee due Apr 10, 2027The maintenance fee for Reducing the Accumulation of Imines/Enamines for the Production of Amino Acids or Amino Acid-Derived Products (US 11,781,163) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 3 fees due May 5 to 26, 2027 · next May 5
- 1 fee due Jun 10, 2027The maintenance fee for Modified Membrane Permeability (US 10,501,503) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 2 fees due Jul 12 to 21, 2027 · next Jul 12
- 1 fee due Sep 10, 2027The maintenance fee for Expression of Klebsiella Oxytoca Polypeptides Involved in Lysine Decarboxylation, and Methods and Applications Thereof (US 10,584,149) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 2 fees due Oct 7 to 14, 2027 · next Oct 7
- 1 fee due Nov 12, 2027The maintenance fee for Expression of Polypeptides Involved in Lysine Decarboxylation, and Methods and Applications Thereof (US 10,647,976) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 24 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Purification of Cadaverine | 19 in force | to Dec 2038 |
| Method and System for Extracting Long Chain Dicarboxylic Acid | 3 in force | to May 2040 |
| Method and System for Refining Long Chain Dicarboxylic Acid | 2 in force | to May 2041 |
| Long Chain Dibasic Acid with Low Content of Long Chain Dibasic Acid Impurity of Shorter Carbon-Chain and Preparation Method Thereof | 2 in force | to Jan 2041 |
| Long-Chain Dibasic Acid with Low Content of Monobasic Acid Impurity and the Production Method Thereof | 2 in force | to Jul 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,388,378 | Candida Sake Strain for Producing Long Chain Dicarboxylic Acids In force · High confidence | In force | High confidence | |
| US 9,650,326 | Process for Treating Reaction Solution Containing Long Chain Dicarboxylate In force · High confidence | In force | High confidence | |
| US 9,546,127 | Purification of Cadaverine In force · High confidence | In force | High confidence | |
| US 9,556,106 | Purification of Cadaverine Using High Boiling Point Solvent In force · High confidence | In force | High confidence | |
| US 9,896,409 | Purification of Cadaverine Using High Boiling Point Solvent In force · High confidence | In force | High confidence | |
| US 9,914,694 | Purification of Cadaverine Using High Boiling Point Solvent In force · High confidence | In force | High confidence | |
| US 9,919,996 | Preparation of Cadaverine In force · High confidence | In force | High confidence | |
| US 10,464,880 | Purification of Cadaverine Using High Boiling Point Solvent In force · Medium confidence | In force | Medium confidence | |
| US 9,234,203 | Stabilized Recombinant Expression Plasmid Vector in Hafnia Alvei and Applications Thereof In force · High confidence | In force | High confidence | |
| US 10,221,407 | Stabilized Recombinant Expression Plasmid Vector in Hafnia Alvei and Applications Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 49: 3 patents in force now held by others · 15 applications pending · 3 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.